CIViC Evidence Items

144 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
D	ERBB2	L755S	Predictive	Supports	Resistance	Breast Cancer	Lapatinib	Bose et al., 2013
D	ERBB2	G309A	Predictive	Supports	Sensitivity/Response	Breast Cancer	Neratinib	Bose et al., 2013
D	ERBB2	L755S	Predictive	Supports	Sensitivity/Response	Breast Cancer	Neratinib	Bose et al., 2013
D	ERBB2	L755W	Predictive	Supports	Sensitivity/Response	Breast Cancer	Neratinib	Bose et al., 2013
D	ERBB2	G778_P780dup	Predictive	Supports	Sensitivity/Response	Breast Cancer	Neratinib	Bose et al., 2013
D	ERBB2	R678Q	Predictive	Supports	Sensitivity/Response	Breast Cancer	Neratinib,Lapatinib	Bose et al., 2013
D	ERBB2	R896C	Predictive	Supports	Sensitivity/Response	Breast Cancer	Neratinib	Bose et al., 2013
D	ERBB2	V777L	Predictive	Supports	Sensitivity/Response	Breast Cancer	Neratinib	Bose et al., 2013
D	ERBB2	V842I	Predictive	Supports	Sensitivity/Response	Breast Cancer	Neratinib	Bose et al., 2013
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab	Slamon et al., 2001
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab	Marty et al., 2005
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Docetaxel,Trastuzumab,Pertuzumab	Swain et al., 2015
B	ERBB2	Exon 20 Insertion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trastuzumab Deruxtecan	Li et al., 2022
A	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Breast Cancer	Margetuximab	Rugo et al., 2021
A	ERBB2	Overexpression	Predictive	Supports	Sensitivity/Response	Solid Tumor	Trastuzumab Deruxtecan	Meric-Bernstam et al., 2024
D	ERBB2	D769H	Predictive	Supports	Sensitivity/Response	Breast Cancer	Neratinib,Lapatinib	Bose et al., 2013
D	ERBB2	D769Y	Predictive	Supports	Sensitivity/Response	Breast Cancer	Neratinib	Bose et al., 2013
B	ERBB2	SERUM LEVELS	Predictive	Supports	Sensitivity/Response	Breast Cancer	Lapatinib	Lee et al., 2016
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Lapatinib,Trastuzumab	Guarneri et al., 2012
B	ERBB2	Amplification	Predictive	Does Not Support	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Lapatinib,Trastuzumab	Zardavas et al., 2015
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,Lapatinib	Blackwell et al., 2010
B	ERBB2	Amplification	Predictive	Does Not Support	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Afatinib	Harbeck et al., 2016
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Gastric Adenocarcinoma	Trastuzumab	Bang et al., 2010
C	ERBB2	Kinase Domain Mutation	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Trastuzumab	Mazières et al., 2016
C	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Lung Small Cell Carcinoma	Trastuzumab,Irinotecan	Kinehara et al., 2015
C	ERBB2	Y772_A775DUP	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Li et al., 2015
D	ERBB2	Y772_A775DUP	Predictive	Supports	Sensitivity/Response	Lung Carcinoma	Afatinib	Perera et al., 2009
D	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Trastuzumab Emtansine	Cretella et al., 2014
B	ERBB2	Amplification	Prognostic	Supports	Poor Outcome	Endometrial Serous Adenocarcinoma		Santin et al., 2005
C	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Endometrial Serous Adenocarcinoma	Trastuzumab	Santin et al., 2008
A	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,Neratinib	Chan et al., 2016
A	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab	Piccart-Gebhart et al., 2005
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Capecitabine,Lapatinib	Geyer et al., 2006
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,Capecitabine	von Minckwitz et al., 2009
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Krop et al., 2014
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Verma et al., 2012
D	ERBB2	V842I	Predictive	Supports	Sensitivity/Response	Colon Cancer	Trastuzumab,Lapatinib,Neratinib	Kavuri et al., 2015
D	ERBB2	L755S	Predictive	Supports	Sensitivity/Response	Colon Cancer	Neratinib,Trastuzumab,Lapatinib	Kavuri et al., 2015
D	ERBB2	V777L	Predictive	Supports	Sensitivity/Response	Colon Cancer	Trastuzumab,Neratinib,Lapatinib	Kavuri et al., 2015
D	ERBB2	L866M	Predictive	Supports	Sensitivity/Response	Colon Cancer	Trastuzumab,Lapatinib,Neratinib	Kavuri et al., 2015
D	ERBB2	S310F/Y	Predictive	Supports	Sensitivity/Response	Colon Cancer	Lapatinib,Neratinib,Trastuzumab	Kavuri et al., 2015
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,Docetaxel,Pertuzumab	Baselga et al., 2012
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab,Lapatinib	Baselga et al., 2012
D	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Pilaralisib,Trastuzumab	Chakrabarty et al., 2013
A	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Gastric Adenocarcinoma	Trastuzumab	Bang et al., 2010
B	ERBB2	Amplification	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Bertotti et al., 2011
B	ERBB2	Amplification	Predictive	Supports	Resistance	Colorectal Cancer	Cetuximab	Bertotti et al., 2011
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Lapatinib,Trastuzumab	Sartore-Bianchi et al., 2016
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Burris et al., 2011
B	ERBB2	Overexpression	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Diéras et al., 2017

Page 1 of 3